1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > 2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape

2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape

  • June 2015
  • -
  • Venture Planning Group
  • -
  • 1200 pages

Summary

Table of Contents

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.


2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape
is VPGMarketResearch’s new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years.  The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.


Rationale


The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.  During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.  Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.  The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage


France, Germany, Italy, Japan, Spain, UK, USA  


Worldwide Market Overview


- Five-year test volume and sales projections by country.


- Comprehensive market segmentation analysis, including review

of the market dynamics, structure, size, growth and major suppliers

by country.


- Estimated universe of laboratories performing cancer diagnostic testing

by country.


- Cancer statistics, etiology and recent developments in the

U.S., Europe, and Japan.


Business Opportunities and Strategic Recommendations


- Specific new product development opportunities with potentially

significant market appeal during the next five years.


- Design criteria for new products.


- Alternative market penetration strategies.


- Potential market entry barriers and risks.


Over 200 Current and Emerging Cancer Diagnostic Test


- Biochemical Markers

- Oncogenes

- Growth Factors

- Hormones

- Colony Stimulating Factors

- Lymphokines

- Immunohistochemical Stains, and others.


- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,

Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,

Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,

Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,

Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,

Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,

Tissue Polypeptide Antigen, and others.


Supplier Shares, Sales and Volume Forecasts


- Sales and market shares of major cancer diagnostic product

suppliers by individual test and country.


- Five-year test volume and sales forecasts

for major tumor markers by country and market segment, including:


- Hospitals

- Commercial/Private Laboratories

- Physician Offices/Group Practices

- Cancer Clinics

- Ambulatory Care Centers


Instrumentation Review


- Analysis of major molecular diagnostic and immunodiagnostic analyzers

used for cancer testing, including their operating characteristics,

features and selling prices.


Technology Assessment


- Assessment of latest molecular diagnostic methods,

biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,

chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies

and their potential applications for cancer diagnostic testing.


- Review of competing/complementing technologies, including

CT, MRI, NMR, PET and photonics spectroscopy.


- Extensive listings of companies, universities

and research centers developing new cancer diagnostic tests

and detection technologies.


Competitive Strategies


- Strategic assessments of major suppliers

and start-up firms developing innovative

technologies and products, including their sales,

product portfolios, marketing tactics, collaborative

arrangements, and new products in R&D.


- The companies analyzed in the report include 


   - Abbott

   - AdnaGen

   - Agilent Technologies

   - Applied Gene Technologies

   - Arca Pharma

   - Beckman Coulter/Danaher

   - Becton Dickinson

   - Biomedical Diagnostics

   - bioMerieux

   - Bio-Rad

   - CellSearch

   - Cepheid

   - Correlogic Systems/Vermillion

   - Decode Genetics

   - Diadexus

   - Diagnocure

   - DiaSorin

   - Eiken Chemical


   - Elitech Group


   - Epigenomics

   - Enterix

   - Enzo Biochem

   - Exact Sciences

   - Fujirebio

   - Guided Therapeutics

   - Hologic/Gen-Probe

   - Kreatech/Leica

   - Kyowa Medex

   - Mackay Life Sciences

   - Myriad Genetics

   - OncoLab

   - Ortho-Clinical Diagnostics

   - Panacea Pharmaceuticals

   - Polartechnics

   - Polymedco

   - PreMD

   - Qiagen/Ipsogen

   - Quest Diagnostics

   - Radient Pharmaceuticals

   - Roche

   - Scienion

   - Sequenom

   - Siemens Healthcare

   - Takara Bio

   - Targeted Diagnostics & Therapeutics

   - Thermo Fisher

   - Tosoh

   - Veridex

   - Wako Pure Chemicals

   - Wallac/PE

   - Zilla



Contains 1,200 pages and 450 tables

“2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape” is VPGMarketResearch’s new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Therapy Market and Monoclonal Antibody Market in the Netherlands

  • April 2017
    13 pages
  • Therapy  

    Monoclonal Anti...  

    Targeted Therap...  

  • Netherlands  

View report >

Pain Relief Industry in Ethiopia

  • April 2017
    8 pages
  • Pain Relief  

    Salicylic Acid  

    Dermatological ...  

  • Ethiopia  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.